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ABSTRACT Pseudomonas aeruginosa is an antibiotic-refractory pathogen with a large genome and extensive genotypic diver-
sity. Historically, P. aeruginosa has been a major model system for understanding the molecular mechanisms underlying type I
clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein (CRISPR-Cas)-based bacte-
rial immune system function. However, little information on the phylogenetic distribution and potential role of these CRISPR-
Cas systems in molding the P. aeruginosa accessory genome and antibiotic resistance elements is known. Computational ap-
proaches were used to identify and characterize CRISPR-Cas systems within 672 genomes, and in the process, we identified a
previously unreported and putatively mobile type I-C P. aeruginosa CRISPR-Cas system. Furthermore, genomes harboring non-
inhibited type I-F and I-E CRISPR-Cas systems were on average ~300 kb smaller than those without a CRISPR-Cas system. In
silico analysis demonstrated that the accessory genome (n 22,036 genes) harbored the majority of identified CRISPR-Cas tar-
gets. We also assembled a global spacer library that aided the identification of difficult-to-characterize mobile genetic elements
within next-generation sequencing (NGS) data and allowed CRISPR typing of a majority of P. aeruginosa strains. In summary,
our analysis demonstrated that CRISPR-Cas systems play an important role in shaping the accessory genomes of globally dis-
tributed P. aeruginosa isolates.
IMPORTANCE P. aeruginosa is both an antibiotic-refractory pathogen and an important model system for type I CRISPR-Cas
bacterial immune systems. By combining the genome sequences of 672 newly and previously sequenced genomes, we were able
to provide a global view of the phylogenetic distribution, conservation, and potential targets of these systems. This analysis iden-
tified a new and putatively mobile P. aeruginosa CRISPR-Cas subtype, characterized the diverse distribution of known CRISPR-
inhibiting genes, and provided a potential new use for CRISPR spacer libraries in accessory genome analysis. Our data demon-
strated the importance of CRISPR-Cas systems in modulating the accessory genomes of globally distributed strains while also
providing substantial data for subsequent genomic and experimental studies in multiple fields. Understanding why certain ge-
notypes of P. aeruginosa are clinically prevalent and adept at horizontally acquiring virulence and antibiotic resistance elements
is of major clinical and economic importance.
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Pseudomonas aeruginosa is a ubiquitous organism that colo-nizes a wide variety of surfaces and aquatic environments (1).
In health care settings, it is a frequent end-stage colonizer in the
lungs of cystic fibrosis patients and a common opportunistic
pathogen of nosocomial wound, pneumonia, and catheter infec-
tions (2). P. aeruginosa is capable of acquiring resistance to all
antibiotics commonly used against it through horizontal gene
transfer and/or by obtaining site-specific mutations within chro-
mosomal elements (3). Determining why some P. aeruginosa lin-
eages are clinically widespread and proficient at horizontally ac-
quiring virulence and antibiotic resistance elements is of high
scientific importance.
Multilocus sequence typing (MLST) studies have shown that
P. aeruginosa has a nonclonal population, with globally dissemi-
nated epidemic clones of highly successful multidrug-resistant
(MDR) P. aeruginosa strains that readily accumulate mobile ge-
netic elements (4, 5). As observed with other pathogens (6), cer-
tain phylogenetically related P. aeruginosa MLST sequence type
(ST) groups aremore common in nosocomial and environmental
settings (7–9). These global clones are multidrug-resistant and
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extensively drug resistant, with the most notable having STs 111
and 235 (4, 5, 10–12). The genomic sequence of the PAO1 strain
was published in the year 2000 and was soon followed by those of
several additional reference strains and clinical isolates (1, 5, 7, 8,
13–16). These sequencing efforts revealed genome sizes ranging
from 5.5 to 7megabase pairs (Mb), GC contents of 65 to 76%, and
79 regions of extensive genome plasticity (16, 17). Over the last
year, Kos et al. added an additional 390 genomes, and for 388
strains, susceptibility data for four antibiotics to the public do-
main, greatly increasing, yet still not saturating, the genomic and
phenotypic information available forP. aeruginosa (5). Compared
to other bacterial pathogens, P. aeruginosa has a large genome,
encoding many diverse horizontally transferable elements, in-
cluding plasmids, conjugative elements, prophages, genomic is-
lands, pathogenicity islands, integrons, and transposons (16, 17).
The major differences in gene contents between isolates necessi-
tate additional genome sequencing and annotation studies to ac-
curately quantify the pangenome and to associate phenotypic
traits with more conserved or less conserved genetic loci (16, 17).
Clustered regularly interspaced short palindromic repeat
(CRISPR) arrays and CRISPR-associated genes (cas) comprise
bacterial adaptive immune systems and function as a variable ge-
netic element. Multiple reports have suggested that CRISPR-Cas
systems may play a major role in controlling horizontal gene
transfer and, consequently, the dynamics of antibiotic resistance
gene acquisition in this important human pathogen (5, 12).
CRISPR-Cas bacterial immune modules protect bacteria and
archaea from mobile genetic elements, such as plasmids and bac-
teriophages (phages) (18, 19). Type I CRISPR arrays are tran-
scribed as one large transcript that is processed within an identical
repeat sequence into mature, small CRISPR RNAs (crRNAs) by a
subtype-specific Cas6 protein (20, 21). Mature crRNAs are then
incorporated into subtype-specific, large riboprotein complexes
and guided to double-stranded DNA (dsDNA) targets in a
sequence-dependent manner (21–24). Once targeted, the ribo-
protein complex interacts with a subtype-specific Cas3 protein,
which enzymatically mediates single-strand nicking and digestion
of the target DNA (25–27). Currently, six known type I subtypes
have been identified and are abbreviated I-A, I-B, I-C, I-D, I-E,
and I-F (28). Importantly, the type I CRISPR-Cas subtypes are
evolutionarily distinct; even within a single bacterial species, they
have a conserved function, and yet, they have very limited se-
quence conservation at both the nucleotide and protein level (28).
The protein complexes, enzymatic activities, and nucleic acid tar-
get preferences of type I, II, and III CRISPR-Cas systems are also
highly divergent and are not necessarily analogous between sys-
tems (28). The ability of the three phylogenetically diverse and
functionally distinct CRISPR-Cas systems to act as prokaryotic
adaptive immunity modules is now well established; however,
their role in shaping bacterial genomes on a species scale is only
now being elucidated. Studies in Enterococcus spp. have suggested
that type II CRISPR-Cas systems reduce the acquisition of antibi-
otic resistance and are negatively associated with MDR strains
(29). However, recent studies in Francisella spp. have indicated
that similar type II CRISPR-Cas systems are critical for increased
antibiotic tolerance through enhancing envelope integrity (30).
P. aeruginosa genomes have not been shown to contain type II
CRISPR-Cas systems; however, they contain prophages encoding
CRISPR-inhibiting genes that are capable of specifically deactivat-
ing the type I-F and I-E CRISPR-Cas subtypes (31, 32). Currently,
it is still unclear what role, if any, CRISPR-Cas systems play in
antibiotic resistance or in shaping the P. aeruginosa accessory ge-
nome.
Here, we examine the phylogenetic distribution and conserva-
tion of CRISPR-Cas systems among 672 P. aeruginosa isolates.
Our analysis identified multiple distinct lineages harboring an in-
tegrative and conjugative element (ICE)-encoded type I-C
CRISPR-Cas system, which had previously never been identified
in P. aeruginosa. Our correlation of phylogeny and spacer content
provide a strong foundation for potentially utilizing CRISPR typ-
ing to rapidly determine the lineages (ST groups) of a majority of
P. aeruginosa isolates. Furthermore, the frequency of spacer inte-
gration and deletion observed between related strains indicates
that CRISPR typing may be useful in tracking strains within out-
breaks, even if they are of the same ST group. The global spacer
library that was assembled also aided in the identification of
difficult-to-characterize mobile genetic elements within next-
generation sequencing (NGS) data anddemonstrated that thema-
jority of spacer targets resided within the P. aeruginosa accessory
genome. Interestingly, after correcting for the presence of anti-
CRISPR genes, it was found that type I-F and I-E CRISPR-Cas
systems were correlated with decreased genome size. Altogether,
our analysis reveals that CRISPR-Cas systems play an important
role in shaping the accessory genomes of globally distributed
P. aeruginosa strains and provides a substantial data set for future
CRISPR-Cas and genomics studies.
RESULTS
Clinical P. aeruginosa strain collection and population struc-
ture.Tounderstand the genomic diversity ofP. aeruginosa clinical
isolates, we compared the sequences of 672 strains belonging to
three diverse collections. We sequenced 282 clinical isolates ob-
tained from either the private bioMérieux clinical strain collection
(n  219) or the previously phenotypically characterized Pirnay
collection (n  63) (33). The assemblies of these isolates were
submitted to GenBank with BioProject record number
PRJNA297679. The vast majority of bioMérieux strains were ob-
tained from the European Union and the United States over a
period of 25 years and represent primarily human-derived isolates
(214/219). The strains from the globally distributed and tempo-
rally wide-ranging Pirnay collection are predominantly clinical in
nature; however, five strains from nonhospital settings were in-
cluded as an environmental outgroup (33). The genomic and/or
phenotypic information of strains recently sequenced (n  390)
and phenotypically analyzed (n 388) by Kos et al. were included
in our analysis to obtain a unified and truly large-scale view of
P. aeruginosa clinical isolate diversity. The Kos collection clinical
isolates were also from diverse geographic locations but tempo-
rally range between 2003 and 2012 (5). Importantly, this library of
strains focuses largely on isolates obtained from non-cystic fibro-
sis infections. This choice wasmade because P. aeruginosa isolated
from the cystic fibrosis lung are often distinct from themajority of
environmental or acute-infection-causing strains. Our analysis
showed that the genome sizes range between 5.5 and 7.6 Mb,
which is similar to the size range previously reported by smaller-
scale studies (16, 17).
MLST was employed to compare the phylogenetic diversity of
these 672 isolates with the phylogenies found by prior, non-NGS
studies (see the supplemental material). MLST relies on compar-
ing the sequences of evolutionarily conserved but polymorphism-
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harboring genes (acs, aro, gua, mut, nuo, pps, and trp) in order to
cluster phylogenetically related strains into ST lineages within a
single bacterial species (4). MLST coverage of the 672-strain li-
brary spanned 216 STs, with 52% of strains falling into 22 STs,
clearly demonstrating the diversity of the collection (Fig. 1A). As
noted above, the predominant clonal ST lineages were ST235 and
ST111 (5, 7, 8). Among the 282 newly sequenced strains, MLST
analysis assigned 41 STs that were previously uncatalogued (see
Table S1 in the supplementalmaterial). The identification of novel
STs is interesting, yet not unexpected for a phylogenetically di-
verse and genetically promiscuous pathogen like P. aeruginosa.
Together, these phylogenetic analyses clearly demonstrate both
the diversity of P. aeruginosa strains capable of causing human
infections and the increasing nosocomial fitness of selectP. aerugi-
nosa lineages as they predominate in the clinic.
Identification and annotation of the P. aeruginosa common
pangenome. P. aeruginosa is well known for its relatively large
genome, which contains both a substantial invariable core ge-
nome and strain-specific accessory genes that, combined, consti-
tute the pangenome (16). All 672 genomes were uniformly anno-
tated using the commercially available Archetype genomics
pipeline. CD-HIT clustering, an algorithm that collapses similar
protein sequences into cluters, was used to create a non-
redundant catalog of protein-coding sequences from the
P. aeruginosa genomes (see the supplemental material). This anal-
ysis, using a 70% amino acid identity cutoff, reduced the protein-
coding pangenome of our P. aeruginosa combined library from
over 4 million protein sequences to roughly 27,000 (Fig. 1B; see
also Table S2 and Text S1 in the supplemental material). Interest-
ingly, a quarter of all pangenome gene clusters are singletons, rep-
resenting a single unique gene found only in a single genome.
Although it is possible that some of these proteins were not anno-
tated in other genomes, these results suggest a substantial reser-
voir of unique singleton genes within the P. aeruginosa popula-
tion.
Rarefaction curves showed that the number of CD-HIT clus-
ters continues to increase with the number of P. aeruginosa ge-
nomes sequenced, although at a decreased rate (Fig. 1B). Extrap-
olation from the rarefaction curve suggests that we have largely
identified all accessory genomic elements found in multiple
strains (common accessory genome) and that sequencing addi-
tional similar P. aeruginosa clinical isolate genomes will yield
roughly 10 or fewer new singletons per genome sequenced
(Fig. 1C). CD-HIT analysis of all 672 genomes identified 5,081
clusters found in at least 90% of genomes (see Table S2 in the
supplemental material), closely matching the previous core-
genome value of 5,021 clusters identified by comparing five ge-
nomes (16). A cutoff of 90% rather than 100% was utilized to
prevent exclusion of core-genomic components as a result of the
sequencing coverage gaps that are inherent to large-scale NGS
studies. These data revealed that the sizes of the core and common
accessory genomes will likely vary minimally with additional ge-
nome sequences (16). Together, these analyses provide a global
view of P. aeruginosa clinical isolate genome diversity, including a
comprehensive list of the CD-HIT clusters constituting the cur-
rent pan- and core genomes (see Table S2).
Antibiotic susceptibility testing and resistome identifica-
tion. P. aeruginosa infections refractory to antibiotics are a well-
established clinical problem; however, the emergence of
multidrug-resistant P. aeruginosa (MDRPA), extremely drug-
resistant P. aeruginosa (XDRPA), and pan-drug-resistant
P. aeruginosa (PDRPA) isolates has highlighted the need for novel
FIG 1 Genomic diversity of P. aeruginosa clinical isolates. (A) Phylogenetic tree of P. aeruginosa clinical isolates. Phylogenetically related ST groups with7
members are shown in different colors. The prevalent lineages constitute 52% of all strains analyzed. ST groups that have only 1 member are delineated in grey,
while black denotes phylogenetic lineages with 2 to 6 members. The phylogenetic locations of the common laboratory strains PAO1, PA14, and PA7 are marked
in black for reference, while the 4 nonclinical isolates are labeled with small black asterisks. (B) Rarefaction curve analysis of the total number of genes within the
P. aeruginosa pangenome as a function of the number of genomes sequenced. Extrapolation is shown with dotted lines. (C) Rarefaction curve analysis of the
number of new genes identified as a function of the number of P. aeruginosa genomes sequenced. A distribution of values was obtained for each strain count by
permuting the order of the strains 500 times. The median trend line and 95% confidence intervals are shown in blue.
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antipseudomonal drug development (34, 35). Currently, eight an-
tibiotic classes are used to treat P. aeruginosa infections (amino-
glycosides, carbapenems, cephalosporins, fluoroquinolones,
penicillins in combination with -lactamase inhibitors, mono-
bactams, phosphonic acids, and polymyxins) (see Fig. S1 in the
supplementalmaterial) (36).MDRPA isolates are defined as being
nonsusceptible to1 agent in3 antimicrobial categories, while
XDRPA isolates are nonsusceptible to 1 agent in all but 2
antimicrobial categories (36). PDRPA isolates, so-called super
bugs, are nonsusceptible to all major antipseudomonal antibiotics
in clinical use (36). Recent studies have identified ST groups 111
and 235 as major MDR lineages (5, 7, 8).
To better understand the antibiotic resistance profiles of all
newly sequenced strains and identify MDRPA and XDRPA iso-
lates, we performed broth dilution assays complemented with Vi-
tek testing for all 282 newly sequenced isolates using four clinically
relevant antibiotics from distinct antimicrobial categories (ami-
noglycosides, penicillins plus beta-lactamase inhibitors, carbap-
enems, and cephalosporins). Additionally, most strains were
tested for multiple other clinically relevant antibiotics from the
remaining antipseudomonal antibiotic families (fluoroquinolo-
nes, phosphonic acids, monobactams, and polymyxins). The
known resistance genes of all newly sequenced strains were com-
putationally identified and combined with phenotypic and ge-
netic data previously obtained for the Kos collection (see Table S1
in the supplemental material) (5). Unsurprisingly, the link be-
tween known resistance genes and phenotypic antibiotic resis-
tance was stronger for some antibiotics than for others, an obser-
vation previously made by Kos et al. (5).
Between the Kos collection antibiotic screening (four antimi-
crobial categories tested) and our analysis, we identified 246
MDRPA isolates and 31 XDRPA isolates (Fig. 2; see also Table S1
in the supplemental material). These data demonstrate that at
least 41% of the clinical strains analyzed are atminimumMDRPA
according to the breakpoints established by the Clinical and Lab-
oratory Standards Institute (CLSI) (36). Alarmingly, we identified
eight isolates that were nonsusceptible to at least one antibiotic
from all eight antibiotic categories (see Table S1). After assigning
the ST type of each MDRPA and XDRPA isolate, we identified
eight STs that appeared enriched in MDRPA/XDRPA isolates
(Fig. 2). Importantly, the resistance-enriched STs represented
clades containing five or more MDRPA/XDRPA isolates, regard-
less of the number of strains within the ST. This cutoff by design
excludes STs containing less than four isolates and ismore likely to
include larger STs prevalently found within the clinic and, conse-
quently, our library. As expected, the previously characterized and
clinically problematic STs 111 and 235 were both designated as
enriched in drug resistance. ST348, which is oddly bisected by the
small but highly drug-refractory ST1320, was also shown to har-
bor multiple drug-resistant strains (Fig. 2). Interestingly, the
placement of ST1320 within the ST348 clade likely indicates that
these strains are members of a larger clonal complex. Of further
interest, the remaining five drug resistance-enriched STs harbor
numbers of strains similar to the numbers in many other
medium-sized STs; however, they still contain at least five
MDRPA or XDRPA strains. Only 4 of the 8 drug-resistant STs
(STs 235, 111, 348, and 244) were in the top 10most prevalent STs
identified in the entire collection (Fig. 1A and 2). ST357, which is
related to the well-characterized ST235 group, is especially threat-
ening. While our library contains only seven ST357 isolates, three
are MDRPA and two are XDRPA. Furthermore, one of the
XDRPA strains is nonsusceptible to at least one antibiotic from all
eight clinically used antimicrobial categories. The nosocomial or-
igin and antibiotic-refractory nature of these eight STs suggests
that these lineages may represent current or emerging high-risk
MDRPA clades. Furthermore, the combined antibiotic suscepti-
bility and genomic data set allows a better understanding of the
phylogenetic distribution of known resistance elements; however,
these data are also invaluable in understanding how CRISPR-Cas
systems may modulate antibiotic resistance in P. aeruginosa.
Phylogenetic distribution ofCRISPR-Cas subtypes and anti-
CRISPR within clinical P. aeruginosa isolates. P. aeruginosa has
emerged as a major CRISPR-Cas model system (20, 22, 24, 31, 32,
37); however, only two studies have ever attempted to understand
the diversity and conservation of their CRISPR-Cas systems (38,
39). Themore comprehensive of these two studies was performed
before thewidespread use ofNGS, andwhile informative, it lacked
the sequencing depth and breadth required to illustrate the scope
of CRISPR-Cas-mediated interactions in P. aeruginosa (38). Ad-
ditionally, in the past 5 years, important advancements have been
made in understanding the molecular mechanism underlying
CRISPR-Cas function, as well as the identification of genes encod-
ing CRISPR-Cas-inactivating proteins (31, 32), enabling a more
thorough computational analysis. Utilizing our substantial
genomic library, we strove to perform a new large-scale analysis of
CRISPR-Cas phylogenetic distribution, conservation, and target-
ing.
Computational analysis identified intact type I-F and type I-E
CRISPR-Cas subtypes in 202 and 81 genomes, respectively
(Fig. 3A; see also Table S3 and Fig. S2 in the supplemental mate-
rial). Both subtypes uniformly localized to previously identified
genomic loci (Fig. 3B) (38). We also identified 20 P. aeruginosa
isolates harboring the type I-C CRISPR-Cas system, which had
previously never been identified in P. aeruginosa (Fig. 3A and B;
see also Table S3 and Fig. S2). The type I-C systems were distrib-
FIG 2 Known and potential new MDRPA lineages. Phylogenetic tree illus-
trating the locations of ST groups harboring 5 MDR strains (colored
branches), 2 to 4 MDR strains (black branches), or 0 or 1 MDR strain (grey
branches). Black spikes protruding from the circle denote the locations of
XDRPA strains.
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uted among eight ST groups. However, most type I-C-positive
strains were clustered into MDRPA groups ST277 and ST235
(Fig. 3A). Unlike the type I-F and I-E subtypes, the type I-C
CRISPR-Cas systems were all carried on pKLC102-like ICEs. The
pKLC102-like ICEs are 100 kb in size and encode both conju-
gation and chromosomal integration machinery (40). ICEs are
widespread inP. aeruginosa and otherGram-negative bacteria and
are usually found integrated into the host chromosome at tRNA
genes which encode their specific bacterial attachment (attB) sites
(40). Only 9 of our 20 type I-C-harboring pKLC102-like elements
had contig sizes large enough to determine the integration site;
however, in all 9 cases, the integration site was in a tRNALys gene
(PA0976.1 or PA4541.1). As these are the only two tRNALys loci in
the P. aeruginosa genome and perfectly match the established attB
site for pKLC102-like elements, we can infer that most if not all
type I-C-harboring ICEs are integrated at one of these two sites
(Fig. 3B). This analysis represents both the first report of a type I-C
CRISPR-Cas system in P. aeruginosa and the first putatively mo-
bile genetic element with a CRISPR-Cas system in a Pseudomonas
species.
Specific P. aeruginosa lineages lack both CRISPR arrays and cas
genes (STs 155, 179, 111, 27, 313, 316, 446, and 298), while others
harbor degenerate systems containing CRISPR arrays but lacking
cognate cas genes (STs 308, 175, and 348). The 84 P. aeruginosa
strains containing CRISPR arrays but lacking cognate cas genes do
not possess cas gene-targeting spacers and no longer encode the
FIG 3 Distribution of CRISPR-Cas systems in P. aeruginosa. (A) Locations of CRISPR-Cas subtypes and anti-CRISPR-Cas genes among the 672 genomes
analyzed. Purple, yellow, and red markers denote the locations of I-F, I-E, and I-C subtypes, respectively. Strains encoding CRISPR-Cas-inhibitory proteins are
denoted in violet for type I-F and orange for type I-E. The locations and colors of major STs are highlighted identically to their depiction in Fig. 1A to aid in
orientation. Degenerate type I-F systems lacking cas genes are denoted by short purple bars. (B) Diagram of the conserved gene content and location of each
CRISPR-Cas subtype. Colored diamonds denote subtype-specific CRISPR repeats, while multicolored squares denote unique spacer content. (C) Heatmap
illustrating that CRISPR array spacer content associates with phylogeny. The presence of every unique spacer sequence in each CRISPR-positive strain is denoted
by blue squares. All strains are grouped by ST along the y axis, as denoted by various colors. The 3most prevalent STs harboring each CRISPR subtype are shown.
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Cas enzymes required to process or utilize the CRISPR array tran-
scripts (see Fig. S2 in the supplementalmaterial). Nearly all strains
in the major STs 348 (21/21) and 308 (15/16) have a detectable
CRISPR array without cognate cas genes (Fig. 3A). Additionally,
previous studies in P. aeruginosa have identified small proteins
which can functionally deactivate CRISPR-Cas type I-E and I-F
systems (31, 32, 41). Currently, eight known groups of anti-
CRISPR genes (four anti-type I-F and four anti-type I-E genes)
have been characterized; however, there are likely to be additional
anti-CRISPR genes as yet unidentified, including those targeting
the newly identified I-C subtype. Anti-CRISPR genes were widely
identified in many diverse strains and groups, with potential
CRISPR-Cas type I-E inhibition being particularly apparent in
groups ST395 (13/14) and ST319 (7/7) (Fig. 3A). Interestingly,
this information indicates that many strains with intact CRISPR-
Cas systems are likely to be phenotypically CRISPR-Cas incompe-
tent because they encode a cognate anti-CRISPR protein that de-
activates the correspondingCRISPR-Cas system. Subtype-specific
anti-CRISPR genes were identified in 40 (19.8%) of 202 strains
with I-F CRISPR-Cas subtypes and 43 (53.0%) of 81 strains har-
boring I-E subtypes (see Fig. S2). While previous studies have
demonstrated the function of type I-F and I-E anti-CRISPR genes
(31, 32), this is the first study to identify their wide-spread phylo-
genetic distribution in P. aeruginosa clinical isolates.
Phylogenetic distribution of CRISPR-targeting spacer con-
tent. CRISPR arrays contain a series of sequence-specific con-
served repeats flanking unique inserts known as spacers. New
spacers are derived from invading mobile genetic elements and
integrated into CRISPR arrays through the activity of Cas proteins
(19). Each spacer encodes the targeting sequence of a given
CRISPR array-derived small crRNA (18, 24). The spacer se-
quences of a given bacterial strain therefore constitute a history of
past CRISPR-Cas-mediated interactions. Studies in Salmonella,
Campylobacter, Mycobacterium, and Corynebacterium isolates
have shown that comparing the spacer sequences of a given strain
can provide a phylogenetic bar code to rapidly track pathogenic
strains during outbreaks in a process termed CRISPR typing
(42–47).
CRISPR typing is of particular interest to clinicians attempting
to track outbreaks as it only requires the sequencing of a few loci
rather than the ~7 loci used for MLST typing. However, a strong
link between phylogeny and CRISPR array sequence must first be
experimentally established for a given pathogen, as spacer content
may change over time (19, 22). To determine if there is a strong
association between phylogeny and subtype-specific spacer con-
tent in this diverse P. aeruginosa library, we directly compared the
spacer content of all strains within our collection. A full spacer
library was created by orienting and extracting all spacer se-
quences based on the conserved direct repeatmotif (Fig. 4; see also
Table S4 in the supplemental material). The full spacer library of
11,041 sequences was then collapsed by CD-HIT clustering to
remove all redundant spacers with a 90% identity cutoff, thereby
creating a nonredundant spacer library (Fig. 4; see also Table S4).
By mapping the presence or absence of every unique spacer se-
quence found in the nonredundant spacer library (see Table S4)
(2,214 type I-F, 452 type I-E, and 160 type I-C) for each strain
harboring aCRISPR array (see also Table S3), we identified strains
harboring similar spacer contents (Fig. 3C; see also Fig. S3). The
clustering of spacer-positive strains by ST grouping in all three
CRISPR-Cas subtypes indicates a strong link between phylogeny
and spacer content in P. aeruginosa clinical isolates (Fig. 3C; see
also Fig. S3), similar to observations made for select P. aeruginosa
cystic fibrosis isolates (39). Usefully, spacer content can be slightly
variable even within an ST group due to random spacer deletion
or new spacer integration (Fig. 3C). This inter-ST diversity could
provide a powerful tool for tracking sublineages of genetically
similar strains within a hospital outbreak. As CRISPR arrays are
found in 14 of the 22 most common clinical ST groups analyzed,
they may provide considerable value in tracking select P. aerugi-
nosa lineages in nosocomial environments. Together, these anal-
yses provide both theMLST-based phylogenetic data andCRISPR
array sequences required to aid in future P. aeruginosa CRISPR
typing.
Novel approach for highlighting previously uncharacterized
mobile genetic elements in large NGS genome datasets. While
comparison of CRISPR spacer sequences to previously studied
elements within the NCBI database identified potential targets for
roughly 30% of unique spacers, comparison of the remaining
~70% of spacers against non-CRISPR accessory genome elements
within our library identified potential targets for a further ~55%
of spacer sequences (Fig. 4). These data indicate that our genome
library contains a massive archive of unstudied CRISPR-Cas-
targeted genetic elements hidden within the larger accessory
genomic sequences. Unfortunately, as the full or partial sequences
of these unstudied mobile genetic elements are unknown and
their full lengths can be split between multiple contigs, standard
homology-based identification is challenging.
As unique CRISPR spacer content primarily represents indepen-
dently acquired and evolutionarily selected short ribonucleoprotein-
targeting sequences with low genomic background complementa-
rity (48), their sequences can be used to highlight previously
encountered genetic elements within complex genomic data. Akin
to antibodies, spacer sequences are the adaptive targeting element
of an immune systemand are rarely retainedwithin the host if they
are cross-reactive. By identifying NGS contigs harboring large
clusters of novel spacer target sequences, we can rapidly highlight
P. aeruginosa mobile genetic elements not currently annotated
within the NCBI database (Fig. 4). As a proof of principle, we
utilized our spacer library to identify novel mobile genetic ele-
ments commonly contained within the accessory genomes of the
clinically problematic MDRPA ST111 lineage of P. aeruginosa.
As ST111 forms a globally disseminated, highly antibiotic-
resistant, CRISPR-Cas-devoid, and clinically prevalent lineage of
P. aeruginosa, it represents the perfect test case to identify novel
mobile genetic elements. By comparing the unique spacer library
against all contigs within ST111 P. aeruginosa genomes, we iden-
tified a few mobile genetic elements commonly found in ST111
strains (Fig. 4; see also Table S5 in the supplemental material).We
identified one pKLC102-like ICE with sequence similarity to a
previously sequenced element found in P. aeruginosa strain PA7
(15); interestingly, it was present in 67% of ST111 strains. Addi-
tionally, three novel prophages were identified, which were found
in 27%, 12%, and 48% of ST111 strains and were most similar to
LESB58 prophage 5, M18 prophage I, and PA7 prophage RGP78,
respectively (Fig. 4; see also Table S5) (14, 15, 49). As both ICEs
and bacteriophages have been shown tomodulate the virulence of
P. aeruginosa, the role of these four novel elements in ST111 vir-
ulence should bemore thoroughly analyzed in future studies. This
small-scale examination demonstrates that large spacer libraries
can be used to highlight novel NGS elements for further analysis
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(see the supplementalmaterial). Lastly, these data support the idea
that P. aeruginosa CRISPR-Cas systems interact both with known
accessory genomic elements deposited in the NCBI database and
with many previously uncharacterized elements contained within
P. aeruginosa clinical isolates.
CRISPR-Cas systems affect P. aeruginosa genome size and
targetmanypreviously studiedmobile genetic elements.Weob-
served that P. aeruginosa genomes harboring intact CRISPR-Cas
type I-F or I-E systems and lacking known cognate anti-CRISPR
genes were on average significantly smaller in size (~300 kb) than
those without a CRISPR-Cas system (Fig. 5A). Few type I-C-
harboring genomes were available; however, a similar trend in
genome size was also observed for this less prevalent CRISPR-Cas
subtype. These data are consistent with the proposed role of
CRISPR-Cas systems acting to filter horizontal gene transfer into
CRISPR-Cas-encoding strains. To better understand the types of
genetic elements being blocked by the CRISPR-Cas systems, we
compared the unique spacer library obtained from all P. aerugi-
nosa strains analyzed (see Table S4 in the supplemental material)
against the NCBI mobile genetic element libraries.
Computationally calculating the complementarity between
nonredundant spacers and the NCBI plasmid (8,915 plasmids)
and phage (9,448 phages) databases assigned targets for 1% and
26% of the unique spacers, respectively. Interestingly, no spacers
were identified to have complementarity to known integrons,
which aremobile genetic elements encoding a site-specific recom-
binase and, often, antibiotic resistance elements. This was perhaps
expected as integrons are small, often integrated into larger mobile
genetic elements, such as plasmids and transposons, and endow se-
lective advantages upon host cells. However, integrons are wide-
spread in P. aeruginosa and are amajor mechanism by which antibi-
otic resistance is spread within MDRPA. Conversely, many spacers
were identified against known virulence islands and other ICE ele-
ments, likely as a result of their substantial size andmetabolic burden
on host cells. As it is impossible to talk about all of the interesting
CRISPR-Cas targets identified within the NCBI databases, we will
focus our analysis on a few interesting representatives.
Similar to the results of previous smaller-scale studies, more
spacers are complementary to known temperate bacteriophages
than to other mobile genetic elements, such as plasmids, genomic
FIG 4 In silico CRISPR target prediction. CRISPR arrays were computationally identified using PILER-CR and subsequently oriented uniformly. Wavy lines
denote individual P. aeruginosa genomes. Sequences containing type I-C CRISPR arrays are shown with red diamond repeats, while those with I-E or I-F harbor
yellow and purple diamonds, respectively. Conserved repeats of all three subtypes (I-C, I-E, and I-F) were computationally extracted, leaving only spacer content
(rainbow-colored boxes), which provides the sequence specificity required for CRISPR-Cas targeting. Removal of spacer sequences with greater than 90%
identity to other spacers provides a nonredundant spacer library. Unique spacer sequences are shown as different colors across the top of the image. Black squares
indicate the presence of that spacer in a given strain. Spacer complementarity to known viral and plasmid databases indicates substantial CRISPR targeting;
however, themajority of putative spacer targets were found in the accessory genomes of P. aeruginosa strains analyzed in this study. CRISPR-Cas target sequences
(spacers) reside largely in the nonannotated accessory genomes of P. aeruginosa strains analyzed in this study. The pie chart denotes the percentage of unique
spacers with complementarity to a given type of target sequence. Spacer sequences can be used to highlight previously uncharacterized accessory elements that
are likely to be mobile genetic elements. Purple, red, and yellow squares represent the sites of complementarity for nonredundant type I-F, I-C, and I-F spacer
sequences, respectively. 1, 2, and 3 represent prophages predominantly found in the highlyMDR and clinically prevalent ST111 P. aeruginosa lineage, while
ICE1 represents a pKLC102-like element that is highly prevalent in ST111 strains.
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islands, or transposons (see Table S4 in the supplemental mate-
rial) (38). The mosaic nature of bacteriophages coupled with the
rise of bacteriophage sequencing has resulted in an abundance of
spacers that potentially target many different bacteriophages. In-
terestingly, the ability of a single spacer to target many distinct
bacteriophages is likely an evolutionary advantage and possibly a
reason some spacers are retained longer than others. To make
these data understandable and relatively easy to interpret, we have
chosen to list only a single target for each individual spacer, even
though they may provide resistance to other, similar elements. As
previously observed, spacers were identified targeting nearly the
full diversity of known P. aeruginosa temperate bacteriophages
(see Table S4) (38). However, unlike previous studies, we identi-
fied multiple spacers against previously identified and sequenced
lytic bacteriophages (KPP23, KPP25, EL, and P3_CHA) (50–53).
While bacteriophages seem to be the major target of P. aerugi-
nosa CRISPR-Cas systems, many spacer targets were still identi-
fied in previously characterized P. aeruginosa plasmids (Fig. 4 and
5B). Pseudomonas plasmids play a key role in the horizontal trans-
fer of antibiotic resistance genes between strains (54, 55). In total,
29 previously sequenced plasmids were identified from the NCBI
database with some level of spacer target sequences (see Table S4
in the supplementalmaterial). Twoof these plasmids (pBS228 and
pOZ176) have been demonstrated to endow antibiotic resistance
(56, 57). Plasmid pBS228 is virtually identical to the conjugative
Birmingham IncP-1 resistance plasmid PK2/RP4/RP1; however,
pBS228 contains an extra transposon conferring resistance to
streptothricin, streptomycin, spectinomycin, and trimethoprim
(56). Similarly, pOZ176 is a conjugative IncP-2 resistance plasmid
harboring two integrons encoding resistance to aminoglycosides,
carbapenems, chloramphenicol, and carbenicillin (57). Interest-
ingly, no pBS228-like plasmids were identified in our genome li-
brary, and while two MDRPA CRISPR-Cas-deficient strains har-
bored pOZ176-like plasmids, these plasmids did not contain
antibiotic resistance genes. In aggregate, these data indicate that
while P. aeruginosa CRISPR-Cas systems have historically been
FIG 5 Correlations between CRISPR-Cas subtypes and antibiotic resistance. (A) Clinical isolates containing CRISPR-Cas systems have, on average, smaller
genomes than those lacking the same systems. Red, yellow, and purple dots represent the genome sizes of individual strains harboring the respective CRISPR-Cas
system. Blue and grey dots denote the genome sizes of strains either lacking CRISPR-Cas systems or predicted to have CRISPR-Cas systems that are inactivated
by anti-CRISPR-Cas genes, respectively. Box plots illustrate the distribution of genome sizes in each category. The upper and lower “hinges” of each box
correspond to the first and third quartiles of the genome sizes for the clinical isolates in each category. Upper and lower whiskers extend from the given hinge to
the highest or lowest value that is within 1.5* IQR,where IQR is the inter-quartile range, or distance between the first and third quartiles. TheWilcoxon rank-sum
test and t testwere used to compare the distributions of sizes betweenpairs, andmultiple-hypothesis-adjustedP values are provided. (B) Locations of spacer target
sequences in previously sequenced plasmids and pathogenicity islands. The colors correspond to the CRISPR-Cas subtypes depicted in panel A. (C) Correlation
of antibiotic susceptibility with the presence or absence of a given CRISPR-Cas subtype. (D) Correlation of antibiotic resistance genes with the presence or
absence of a given CRISPR-Cas subtype. (C andD)Data are corrected for the presence of anti-CRISPR-Cas genes. The P values are from theWilcoxon rank-sum
test. The false discovery rate (FDR) adjustment of the P values was performed using the Benjamini-Hochberg method with the function p.adjust in R.
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found to target elements within known antibiotic resistance plas-
mids (16), we could not detect these same resistance plasmids in a
library containing a substantial number of MDRPA strains.
As another focused example of the plethora of interesting
CRISPR-Cas-genomic island interactions observed in our data set
(see Table S4 in the supplemental material), we looked closely at a
widely distributed spacer targeting the pilV2 gene of the conjuga-
tive type IVb pilus of pKLC102, PAPI-1, and PAGI-5. While we
identified multiple spacers in many strains targeting these three
widely distributed conjugative elements (Fig. 5B), we chose to
focus on a single spacer targeting pilV2. PilV2 is theminor subunit
of the pilus filament and is required for functional conjugation-
mediated horizontal gene transfer of these and other important
accessory genomic elements (58). As pilV2 is required for function
and is highly conserved between similar conjugative elements, it
provides both a perfect target for the CRISPR-Cas bacterial im-
mune systemand an excellentmarker for determining the carriage
rate of similar elements in our clinical library. Roughly 40% of
clinical isolates within our library contained conjugative elements
harboring a 100% conserved target and protospacer-adjacentmo-
tif (PAM) sequence within the pilV2 gene, clearly indicating the
ubiquity of these elements in the P. aeruginosa global population.
The diversity of genetic elements potentially targeted by
P. aeruginosaCRISPR-Cas systems is striking.However, well char-
acterized mobile genetic elements account for only ~30% of
unique spacer matches, while 55% are complementary to largely
uncharacterized portions of the P. aeruginosa accessory genome.
These data clearly illustrate the need formore accurate curation of
P. aeruginosa accessory genome elements, a challenging process
due to the chimeric nature ofmanymobile elements and the enor-
mous number of P. aeruginosa strains being sequenced. However,
as this study establishes a massive library of spacer sequences to
highlight these interesting elements within NGS data, this chal-
lenge should be more manageable.
Correlations between antibiotic resistance and the presence
or absence of CRISPR-Cas systems in P. aeruginosa. The hy-
pothesis that CRISPR-Cas bacterial adaptive immune systems
prevent clinical isolates from acquiring antibiotic resistance ele-
ments has been widely discussed; however, it has not been docu-
mented outside the enterococci (29). To assess whether CRISPR-
Cas systems play a role in P. aeruginosa antibiotic resistance, we
correlated their presence or absence with phenotypic susceptibil-
ity to clinically relevant antibiotics (31, 32) (Fig. 5C). Importantly,
all of these correlationswere done after correcting for the presence
of subtype-specific anti-CRISPR genes (Fig. 3A and 5A).
The presence of type I-E and I-F CRISPR-Cas subtypes
strongly correlated with the susceptibility of the strain to multiple
clinically relevant antibiotics; however, the presence of these cor-
relations was dependent on the two prevalent MDRPA STs 111
and 235 (Fig. 5C). Puzzlingly, the less prevalent and ICE-localized
type I-C subtype showed a strong correlationwith resistance to the
antibiotic amikacin, a clinically used aminoglycoside (Fig. 5C)
(36). To determine whether known antibiotic resistance genes
also correlated with the presence or absence of each CRISPR-Cas
subtype, statistical analysis was performed for each known resis-
tance gene and allele.We observed that the sulfonamide resistance
gene sul1 was negatively associated with both the type I-E and I-F
system; however, the significance of this correlation was again
dependent on MDRPA STs 111 and 235. The sul1 gene is com-
monly associated with the 3= region of integrons (59), which,
again, often carry a diverse array of other clinically important
antibiotic resistance elements (60, 61). A significant negative cor-
relation was also observed between the type I-F subtype and the
beta-lactamase CARB. Interestingly, we observed positive corre-
lations between the type I-C CRISPR-Cas subtype and the rmtD,
aadA7, and OXA-encoding resistance genes. These data indicate
that correlations between antibiotic resistance and the presence or
absence of CRISPR-Cas systems in P. aeruginosa are being driven
largely by select phylogenetic lineages.
The combined data and associations within this study are con-
sistent with a role for CRISPR-Cas systems in modulating the
movement of mobile genetic elements through the global
P. aeruginosa population. However, we could only identify two
resistance plasmids with complementarity to spacer sequences,
and we found no spacer complementary to integrons or antibiotic
resistance genes. Additionally, both the phenotypic and genotypic
antibiotic resistance/susceptibility correlations with CRISPR-Cas
systemswere heavily dependent on selectMDRPA lineages. Taken
together, these data are most consistent with P. aeruginosa
CRISPR-Cas systems acting to shield bacteria from temperate
bacteriophages or genomic islands rather than blocking the trans-
fer of resistance genes directly.
DISCUSSION
CRISPR-Cas bacterial immune systems are emerging as major
players in bacterial physiology and are increasingly being co-opted
for use in molecular biology, genome engineering, and transla-
tional applications (62). P. aeruginosa is a major CRISPR-Cas
model system (20, 22, 24, 31, 32, 37), an important opportunistic
human pathogen (3), and a common target for phage therapy
applications (63). Together, these attributes highlight the neces-
sity of understanding the ubiquity, conservation, and potential
roles of P. aeruginosa CRISPR-Cas systems. In this study, we as-
sembled and characterized a 672-strain genomic and phenotypic
data set to better understand how CRISPR-Cas systems influence
the composition of the P. aeruginosa accessory genome on a global
scale.
The P. aeruginosa pangenome contains numerous accessory
elements, among which prophages, genomic islands, plasmids,
and CRISPR-Cas systems are some of the most interesting (16,
17). The rarefaction analysis performed in this study demon-
strated that the global pangenome is now better defined and that
we have likely obtained the majority of common elements (nons-
ingletons). Our combined analysis provided useful phylogenetic
information and the experimental sequences for 27,117 unique
pangenome genes. Interestingly, this analysis also found that the
majority of unique spacer sequences (~55%) were complemen-
tary to elements within the pangenome and not the NCBI plas-
mid/phage libraries. These spacer-target data illustrated that a
large reservoir of understudied genetic elements resides within
these genomes. Furthermore, spacer sequences were shown to
have substantial value in rapidly identifying novel mobile genetic
elements in NGS data. As a proof of principle, three novel
prophages and one ICE that are enriched in ST111were identified.
Notably, these 4 mobile elements constitute roughly 215 kb of
accessory DNA per strain, nearly matching the average discrep-
ancy in overall genome size between CRISPR-Cas-intact and
-deficient strains. While determining the role of these elements is
outside the scope of this work, it is tempting to speculate that they
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may be virulence-enhancing elements, as has been observed for
other plasmids and temperate bacteriophages (14, 64, 65).
As CRISPR spacer sequences have also been shown to be valu-
able in characterizing bacterial phylogeny and tracking patho-
genic bacterial outbreaks in a process termed CRISPR typing (42–
45, 66), we aimed to establish a global link between MLST and
CRISPR array sequences in P. aeruginosa. By creating CRISPR
spacer libraries and analyzing the spacer content of each strain
against all others, we were able to establish a strong relationship
between spacer content and phylogeny in CRISPR array-positive
P. aeruginosa isolates. The combination of these data and the se-
quence library potentially supplies the analytical data needed for
clinicians and scientists to utilize CRISPR typing to rapidly iden-
tify and track roughly 60% (152/253) of P. aeruginosa ST lineages.
CRISPR typing, while not universal in P. aeruginosa, could sub-
stantially increase the speed and accuracy of phylogenetic charac-
terization of P. aeruginosa clinical or environmental isolates.
The extensive antibiotic susceptibility testing performed on
our panel of 282 P. aeruginosa isolates coupled with the antibiotic
screening performed by Kos and colleagues has allowed us to bet-
ter characterize MDRPA lineages (5). We found that 41% of
strains analyzed were phenotypically MDRPA or XDRPA, sub-
stantially higher than documented in previous reports (5). Con-
firming previous studies, we identified STs 111 and 235 as the
predominant clinical and MDRPA clonal groups (5, 7, 8). How-
ever, we also identified STs 233, 348, 244, 277, 298, and 357 as
being enriched in drug resistance and poised to emerge as high-
risk clones. Furthermore, this data set allowed for a robust analysis
of howCRISPR-Cas systems impact P. aeruginosa antibiotic resis-
tance, a topic of major interest in multiple fields.
Confirming previous small-scale studies (38, 39), the most
common intact CRISPR-Cas system found in P. aeruginosa is type
I-F (30%), followeddistantly by type I-E (12%).We also identified
a previously unobserved type I-CCRISPR-Cas system encoded on
ICEs within the genomes of 20 strains. Prior to this work, no study
had identified type I-C or putatively mobile CRISPR-Cas systems
in P. aeruginosa. Phylogenetic analysis demonstrated that certain
common P. aeruginosa lineages completely lacked any detectable
CRISPR arrays, while others had degenerate systems harboring
CRISPR arrays but lacking cognate cas genes. Interestingly, some
lineages are nearly uniformly endowed with CRISPR-Cas I-F, I-E,
or I-C subtypes. By further overlaying the presence of established
anti-CRISPR genes (31, 32), we also identified strains and lineages
that are CRISPR-Cas intact, yet likely functionally suppressed.
The wide distribution of known anti-CRISPR genes within the
P. aeruginosapopulation provides important insights for scientists
attempting tomakeCRISPR-Cas-based sequence-specific antimi-
crobials to combat drug-resistant pathogens (67–71). As these an-
timicrobials are likely to be ineffective against bacteria that express
cognate anti-CRISPR proteins, additional studies must be per-
formed to determine the diversity and distribution of new anti-
CRISPR proteins in other antibiotic-resistant pathogens. Impor-
tantly, Cas9-based antimicrobials are likely to be functional in
P. aeruginosa because it harbors only type I CRISPR-Cas systems
and, presumably, only type I anti-CRISPR genes.
Previous highly influential studies have implicated type II
CRISPR-Cas systems both in hindering the acquisition of antibi-
otic resistance in enterococci and in enabling antibiotic resistance
in Francisella (29, 30). However, no link has been identified for
type I CRISPR-Cas systems in antibiotic resistance (72). Utilizing
our diverse data set, we identified strong correlations between
resistance to multiple antibiotics and the absence of type I-F and
I-E CRISPR-Cas systems; however, these correlations largely dis-
appeared when the prevalent and largely CRISPR-Cas-deficient
MDRPA STs 111 and 235 were removed. Conversely, the strong
correlations between antibiotic resistance and the rare type I-C
CRISPR-Cas system likely result from these systems being present
primarily in MDRPA STs 235 and 277. Consistent with the anti-
biotic resistance correlations, associations were also observed for
specific antibiotic resistance genes and alleles. Together, these data
demonstrate a strong correlation between specific CRISPR-Cas
systems and antibiotic resistance/susceptibility; however, they do
not illustrate that CRISPR-Cas systems are directly causing these
lineage-biased correlations. No CRISPR-Cas-targeting spacer se-
quences complementary to any known antibiotic resistance genes
were identified, indicating that P. aeruginosaCRISPR-Cas systems
are not directly targeting resistance elements. While a small num-
ber of spacer target sequences did match known and previously
studied antibiotic resistance-encoding plasmids, no spacer target
sequences were identified against the small but highly prevalent
antibiotic resistance-encoding elements known as integrons.
CRISPR-Cas systems were inversely correlated with genome size
inP. aeruginosa, supporting their now established role in shielding
CRISPR-Cas-intact bacteria from horizontal gene transfer (22,
32). Collectively, these data aremost consistent with P. aeruginosa
CRISPR-Cas systems shielding strains from temperate phage in-
fection rather than blocking the flow of antibiotic resistance ele-
ments.
The outlined analysis of 672 predominantly clinical P. aerugi-
nosa isolates has yielded multiple massive, uniformly annotated
datasets for future investigation. These include an abundance of
experimental antibiotic resistance data for a sequenced strain col-
lection, a considerable accessory genome library, and a wealth of
CRISPR-Cas data. Our phylogenetic analysis of CRISPR-Cas sys-
tems and their cognate anti-CRISPR genes provides a bird’s eye
view of their distribution within the P. aeruginosa population and
will be highly useful to researchers attempting to further our un-
derstanding of the diversity, function, and environmental role of
CRISPR-Cas systems.
MATERIALS AND METHODS
Additional details are provided in Text S1 in the supplemental material.
Clinical isolate strain panels. The bacterial strains analyzed in this
study were derived from either the bioMérieux private clinical strain col-
lection (219 isolates), the Pirnay collection (62 isolates) (33), or the Kos
collection (388 isolates) (5). Information pertaining to each P. aeruginosa
isolate is available in Table S1 in the supplemental material.
Antibiotic susceptibility testing. Broth dilution assays comple-
mentedwithVitek testing (bioMérieux,Marcy-l’Étoile, France)were used
to obtain antibiotic resistance data for all isolates contained within the
bioMérieux and Pirnay strain collections. Resistance data frompreviously
characterized Kos isolates were imported from publically available data
(5). Clinical and Laboratory Standards Institute (CLSI) guidelines were
applied to determine susceptibility, intermediate resistance, or resistance
to individual antibiotics (see Table S1 in the supplemental material).
DNA isolation and genome sequencing. DNA was extracted from
P. aeruginosa cells cultured overnight in LB broth at 37°C under 220 rpm
agitation. DNA samples were prepared using the UltraClean microbial
DNA isolation kit (Mo Bio Laboratories, Carlsbad, CA) essentially ac-
cording to the manufacturer’s instructions. Sequencing was performed
using the Illumina paired-end method with read lengths of 150 bp (Illu-
mina HiSeq 2500; Ambry Genetics, Aliso Viejo, CA). Paired-end libraries
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were prepared using KAPA kits according to the manufacturer’s instruc-
tions (KAPA Biosystems, Wilmington, MA).
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